Sign in to view content

An Analysis of Particle Contamination and Protein Aggregation From Syringes Used for Intravitreal Injection

Jason Noble, MD, FRCSC

Video
Published 2021

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Annual Meeting Talks
2021
Clinical Course and Outcomes at 3 Years After Severe Fungal Endophthalmitis in 14 Eyes Following Contaminated Bevacizumab Intravitreal Injection
Mallika Goyal, MD
Annual Meeting Talks
2018

Category: Instrumentation and Devices

See more